Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Dec 20;21(4):361–370. doi: 10.1093/ijnp/pyx117

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017. Published by Oxford University Press on behalf of CINP.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals. permissions@oup.com

PMC Copyright notice

Figure 3. — Effects of intra-ventral tegmental area (VTA) treatment with SR142948A on locomotor activity. (A) Basal locomotor activity was not affected by 5 days of SR142948A or saline microinfusions. Distance traveled before self-administration was overall higher in the control group in training days 6 to 12 (A1), in fixed ratio 3 (FR3) maintenance sessions (A2), and in cue-reinstatement (cue-reins, A4). (B) In the control group, the net increase in locomotion after methamphetamine (METH) self-administration (post-session – pre-session) was higher compared with SR142948A-treated mice only on training days 9 to 12 (B1). No significant changes between groups were detected in maintenance (B2), extinction sessions (B3), cue-reins, or the last FR3 session (B4). Bonferroni posthoc comparisons: *P<.05, **P<.01, and ***P<.001 vs CONTROL.